Literature DB >> 18194399

Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis.

Ylian S Liem1, Johanna L Bosch, M G Myriam Hunink.   

Abstract

OBJECTIVES: Various utility measures have been used to assess preference-based quality of life of patients with end-stage renal disease (ESRD). The purposes of this study were to summarize the literature on utilities of hemodialysis (HD), peritoneal dialysis (PD), and renal transplantation (RTx) patients, to compare utilities between these patient groups, and to obtain estimates for quality-of-life adjustment in economic analyses.
METHODS: We searched the English literature for studies that reported visual analog scale (VAS), time trade-off (TTO), standard gamble (SG), EuroQol-5D (EQ-5D), and health utilities index (HUI) values of ESRD patients. We extracted patient characteristics and utilities and calculated mean utilities and 95% confidence intervals (CIs) for categories defined by utility measure and treatment modality using random-effects models.
RESULTS: We identified 27 articles that met the inclusion criteria. VAS articles were too heterogeneous to summarize quantitatively and we found only one study reporting HUI values. Thus, we summarized utilities from TTO, SG, and EQ-5D studies. Mean TTO and EQ-5D-index values were lower for dialysis compared to RTx patients, though not statistically significant for TTO values (TTO values: HD 0.61, 95% CI 0.54-0.68; PD 0.73, 95% CI 0.61-0.85; RTx 0.78, 95% CI 0.63-0.93; EQ-5D-index values: HD 0.56, 95% CI 0.49-0.62; PD 0.58, 95% CI 0.50-0.67; RTx 0.81, 95% CI 0.72-0.90). Mean HD versus PD associated TTO, EQ-5D-index and EQ-VAS values were not statistically significantly different.
CONCLUSION: RTx patients tended to have a higher utility than dialysis patients. Among HD and PD patients, there were no statistically significant differences in utility.

Entities:  

Mesh:

Year:  2008        PMID: 18194399     DOI: 10.1111/j.1524-4733.2007.00308.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  62 in total

1.  Cost-effectiveness analysis of the Spanish renal replacement therapy program.

Authors:  Guillermo Villa; Lucía Fernández-Ortiz; Jesús Cuervo; Pablo Rebollo; Rafael Selgas; Teresa González; Javier Arrieta
Journal:  Perit Dial Int       Date:  2011-09-30       Impact factor: 1.756

2.  Predictors of health utility among 60-day survivors of acute kidney injury in the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study.

Authors:  Kirsten L Johansen; Mark W Smith; Mark L Unruh; Andrew M Siroka; Theresa Z O'Connor; Paul M Palevsky
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

3.  Impaired renal function is associated with worse self-reported outcomes after kidney transplantation.

Authors:  Luca Neri; Jonathan Dukes; Daniel C Brennan; Paulo R Salvalaggio; Susmitha Seelam; Srividya Desiraju; Mark Schnitzler
Journal:  Qual Life Res       Date:  2011-04-11       Impact factor: 4.147

Review 4.  A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation.

Authors:  Tom W C Lung; Alison J Hayes; Andrew Hayen; Andrew Farmer; Philip M Clarke
Journal:  Qual Life Res       Date:  2011-04-07       Impact factor: 4.147

5.  Design and rationale of health-related quality of life and patient-reported outcomes assessment in the Frequent Hemodialysis Network trials.

Authors:  Manisha Jhamb; Manjula K Tamura; Jennifer Gassman; Amit X Garg; Robert M Lindsay; Rita S Suri; George Ting; Fredric O Finkelstein; Scott Beach; Paul L Kimmel; Mark Unruh
Journal:  Blood Purif       Date:  2011-01-10       Impact factor: 2.614

6.  Home Dialysis in the Prospective Payment System Era.

Authors:  Eugene Lin; Xingxing S Cheng; Kuo-Kai Chin; Talhah Zubair; Glenn M Chertow; Eran Bendavid; Jayanta Bhattacharya
Journal:  J Am Soc Nephrol       Date:  2017-05-10       Impact factor: 10.121

7.  A systematic review of utility values in children with cerebral palsy.

Authors:  Utsana Tonmukayakul; Long Khanh-Dao Le; Shalika Bohingamu Mudiyanselage; Lidia Engel; Jessica Bucholc; Brendan Mulhern; Rob Carter; Cathrine Mihalopoulos
Journal:  Qual Life Res       Date:  2018-08-02       Impact factor: 4.147

8.  Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia.

Authors:  Matthew S Simon; Maroun M Sfeir; David P Calfee; Michael J Satlin
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 9.  Health-related quality of life outcomes in chronic kidney disease.

Authors:  Ritu K Soni; Steven D Weisbord; Mark L Unruh
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

10.  Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.

Authors:  Aaron M Olden; Robert Holloway
Journal:  J Palliat Med       Date:  2010-01       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.